A New View on Biological Quality Control?

Scroll Down

Quality control is an integral and critical part of biologics development and manufacturing, encompassing both contamination control to data integrity. However, the quality of biologics can be impacted by minor variations in manufacturing processes, a problem seen often during the COVID-19 pandemic.

This article explores the changes made by biopharmaceutical companies and CDMOs to adapt to the “new normal”, drawing from the experiences of quality control experts including Natasha Rivas, Vice President of Quality and Regulatory, at Genezen.

Read the full article here: A New View on Quality Control?

You may also be interested in...

Genezen appoints Chief Commercial Officer to…

  Genezen, a cell and gene therapy Contract Development and Manufacturing...

Read more

Downstream Process Development for Lentiviral Vectors…

Lentiviral vectors (LVV) are commonly used as an efficient and safe...

Read more

Stable cell lines vs transient transfection…

The aim of upstream processing in viral vector development and manufacturing...

Read more

Genezen delivers next phase of cGMP…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more